Stock Ratings / Health Care / CELU / insiders

ABVC (34) CPHI (45) CRVO (29) BCTX (41) ⌘ Pro Terminal →

Celularity Inc. (Class A) (CELU) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.85 -9.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.83

Celularity Inc. (Class A) (CELU) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $27.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.83 (-1.93%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CELU)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY CELU SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.56-19.9% Next Q

Q2 (-2Q)

Grade E$1.25-21.6% Next Q

Q3 (-1Q)

Grade E$0.98-13.3% Next Q

Current

Grade E$0.85-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CELU Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CELU currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.32) and Max Pain ($0.89) forces dealer call-delta covering toward $2.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CELU• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CELU Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CELU Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CELU)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CELU. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CELU)

✓Walkthrough of CELU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CELU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.60%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.82H $0.87L $0.80C $0.85VOL 181.8K

RES: $1.96SUP: $0.66SMA50: $1.32SMA200: $1.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CELU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CELU Butterfly Map → + Track CELU →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -51.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CELU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CELU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CELU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CELU)

Health Care Rank #853 of 1016 ⚔️ ABVC vs CELU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CELU vs. ABVC, CPHI, CRVO, BCTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Celularity Inc. (Class A) (CELU) ranks #853 by composite RQD confidence (34/100, grade E) and #814 by equity capitalization ($27.6M). Within this direct 5-issuer industry benchmark cohort, CELU leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. CPHI currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with CELU at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CELU ACTIVE Celularity Inc. (Class A)	E	34/100	—	24.4%	-35.0%	-9.66%	$27.6M	Benchmark Subject
ABVC ABVC BioPharma Inc.	E	34/100	—	—	-35.0%	-4.59%	$27.8M	/abvc-vs-celu →
CPHI China Pharma Holdings Inc.	D	45/100	—	-3.2%	-11.4%	+4.84%	$28.0M	/cphi-vs-celu →
CRVO CervoMed Inc.	E	29/100	—	—	-35.0%	-20.81%	$26.5M	/crvo-vs-celu →
BCTX BriaCell Therapeutics Corp.	D-	41/100	—	—	—	-5.43%	$28.9M	/bctx-vs-celu →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001752828

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Celularity Inc. (Class A) (CELU) reported GAAP revenue of $26.6M (-51.0% vs. FY2024 revenue of $54.2M , and +16.6% cumulative change since FY2023) , GAAP net income of -$91.7M, operating cash flow of -$13.3M, and free cash flow of -$13.3M (-102.0% YoY). On the balance sheet, CELU closed FY2025 with $107.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$26.6M	-$91.7M	-$13.3M	-$13.3M	$107.3M	—
FY2024 (FY)	2024-12-31	$54.2M	-$57.9M	-$6.4M	-$6.6M	$132.7M	—
FY2023 (FY)	2023-12-31	$22.8M	-$196.3M	-$38.7M	-$38.7M	—	—

3. CELU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CELU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Celularity Inc. (Class A) (NASDAQ: CELU) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.85 (-9.66% 1D, market cap $27.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CELU ranks #853 in composite RQD confidence.

How does CELU compare to ABVC and CPHI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CELU carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 24.4%, and ROIC of -35.0%. By comparison, ABVC (ABVC BioPharma Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $27.8M) and CPHI (China Pharma Holdings Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -11.4%, cap $28.0M). Among the 5-stock peer group, CELU leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CELU?

Per CELU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001752828), Celularity Inc. (Class A) generated $26.6M in revenue (-51.0% YoY), -$91.7M in net income, and -$13.3M in free cash flow against $107.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CELU trading relative to its 50-day, 200-day, and 52-week technical levels?

CELU last traded at $0.85 (-9.66% on volume of 496,842 shares), positioning the stock -35.61% below its 50-day simple moving average ($1.32) and -22.02% below its 200-day simple moving average ($1.09). Across its 52-week range of $0.56 to $2.55, CELU sits at the 14.6% percentile with a 14-day RSI of 35.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.96).

CELU Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are CELU insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CELU leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: CELU RQD Cockpit CELU 12M Forecast CELU Earnings & Move CELU Dividends & DRIP CELU Insiders & 13F CELU Whale Options CELU Profit Sankey CELU News & Why